Loading...
Loading...
- Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus targets with the SARS-CoV-2 target that can run on all ARIES Systems.
- These six and 12-cassette systems are automated molecular diagnostic platforms and produce results in less than two hours.
- Luminex developed the original ARIES SARS-CoV-2 Assay with financial support from BARDA and received an Emergency Use Authorization from FDA for COVID-19 testing in April last year.
- Luminex will submit the targeted multiplex respiratory panel, the ARIES Flu A/B & RSV+SARS-CoV-2 Assay, to the FDA for Emergency Use Authorization as soon as possible.
- Price Action: LMNX stock closed 0.34% lower at $29.56 on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in